Skip to main content

Table 1 Bevacizumab: approved indications in the United States [1]

From: Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

Clinical indication

Combination regimen

Treatment setting

Metastatic colorectal cancer

Intravenous 5-fluorouracil–based chemotherapy

First- or second-line treatment

Metastatic colorectal cancer

Fluoropyrimidine-irinotecan– or fluoropyrimidine-oxaliplatin–based chemotherapy

Second-line treatment in patients who have progressed on a first-line bevacizumab-containing regimen

Non-squamous non-small-cell lung cancer

Carboplatin and paclitaxel

First-line treatment of unresectable, locally advanced, recurrent or metastatic disease

Glioblastoma

Monotherapy

Adult patients with progressive disease following prior therapya

Metastatic renal cell carcinoma

Interferon alfa

Adult patients

Cervical cancer

Paclitaxel and cisplatin or paclitaxel and topotecan

Persistent, recurrent or metastatic disease

Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Paclitaxel, pegylated liposomal doxorubicin or topotecan

Adult patients

Platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancerb

Carboplatin and paclitaxel or carboplatin and gemcitabine chemotherapy (followed by bevacizumab)

Adult patients who have relapsed ≥6 months following last treatment with platinum-based chemotherapy

  1. aEffectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with bevacizumab
  2. bFDA approval granted on 6 Dec 2016 [3]